Intuitive Surgical, Inc.

NASDAQ Global Select
Back to all articles
Slightly Bullish +25

Intuitive Surgical Fell 37% to $355 With This Wall Street Pro Is Calling for $685

📉 ISRG shares dropped 37% year-to-date to $355 after management cut full-year procedure growth guidance to 13.5%-15.5%.

💰 Company beat Q2 estimates with $2.89B revenue (up 18.54%) and non-GAAP EPS of $2.80, topping the consensus.

🛡️ Management repurchased $379 million in Q2 at an average price of $439, above the current trading level.

💸 The company holds a strong balance sheet with $8.6 billion in cash on hand.

📉 U.S. da Vinci procedure growth slowed to 12% in Q2 from 14% in Q1 due to payer dynamics and GLP-1 impacts.

🌏 International procedures grew 21%, with Europe and Asia both posting 20% growth.

🔧 Non-GAAP gross margin expanded to 70.0%, aided by a $36 million tariff refund.

🤖 Da Vinci 5 placements reached 246 of 468 total, representing a 24% increase in U.S. placements.

📈 Recurring revenue now accounts for approximately 85% of the company's total revenue.

🎯 Bernstein analyst targets $685 (92% upside), while the average Wall Street target is $484 (36% upside).

⚠️ Tariff exposure across Mexico, Germany, and China manufacturing compressed valuation multiples.

📉 CEO Dave Rosa cited high-single-digit declines in bariatric cases from GLP-1 usage as a key factor.

Bullish Signals
  • ISRG beat Q2 estimates for the fifth consecutive quarter with revenue growing 19% year-over-year to $2.89 billion.
  • Non-GAAP EPS of $2.80 significantly topped the consensus estimate of $2.5037.
  • Management executed a $379 million stock repurchase in Q2 at an average price of $439, well above the current share price.
  • The company maintains a fortress balance sheet with $8.6 billion in cash reserves.
  • International procedures grew 21% in Q2, demonstrating strong global demand outside the U.S.
  • Non-GAAP gross margin expanded to 70.0%, supported by a $36 million tariff refund and operational efficiency.
  • Da Vinci 5 placements surged 24% in the U.S., indicating successful adoption of the newer robotic platform.
  • Recurring revenue now comprises roughly 85% of total revenue, providing high durability and predictability.
  • Bernstein maintains an Outperform rating with a $685 price target, citing the da Vinci 5 upgrade cycle as a key driver.
Risk Factors
  • Management cut full-year procedure growth guidance to 13.5%-15.5%, down from 18% in 2025.
  • U.S. da Vinci procedure growth decelerated to 12% in Q2 from 14% in the prior quarter.
  • Bariatric cases faced high-single-digit declines due to reduced demand from GLP-1 weight loss drug usage.
  • Tariff exposure across manufacturing hubs in Mexico, Germany, and China compressed valuation multiples.
  • The stock has fallen 37% year-to-date despite the underlying business continuing to grow.
  • Analyst consensus price target of $484 implies a 36% gap from current levels, reflecting near-term uncertainty.
Full Analysis
Intuitive Surgical (ISRG) shares fell 37% to $355 following Q2 earnings, where the company beat revenue estimates with 19% growth and non-GAAP EPS of $2.80. Despite the financial beat, management cut full-year procedure growth guidance for the da Vinci system to a range of 13.5%-15.5%, down from 18% in 2025, causing an 11% single-day drop in stock price. The decline is attributed to specific headwinds including U.S. procedure deceleration due to ACA premium dynamics and GLP-1 drug usage reducing bariatric cases, alongside tariff exposure from manufacturing in Mexico, Germany, and China. Management repurchased $379 million of stock in Q2 at an average price above the current market level, while maintaining a robust cash position of $8.6 billion. Analyst sentiment remains mixed but constructive long-term. Bernstein maintains an Outperform rating with a target of $685, citing the da Vinci 5 upgrade cycle and recurring revenue durability. However, the consensus price target sits at $484, implying roughly 36% upside from current levels as investors weigh near-term volatility against the company's dominant market position and fortress balance sheet.